These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9568678)

  • 1. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
    Salgaller ML; Lodge PA; McLean JG; Tjoa BA; Loftus DJ; Ragde H; Kenny GM; Rogers M; Boynton AL; Murphy GP
    Prostate; 1998 May; 35(2):144-51. PubMed ID: 9568678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
    Murphy G; Tjoa B; Ragde H; Kenny G; Boynton A
    Prostate; 1996 Dec; 29(6):371-80. PubMed ID: 8977634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.
    Lodge PA; Jones LA; Bader RA; Murphy GP; Salgaller ML
    Cancer Res; 2000 Feb; 60(4):829-33. PubMed ID: 10706088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
    Murphy GP; Tjoa BA; Simmons SJ; Jarisch J; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL
    Prostate; 1999 Jan; 38(1):73-8. PubMed ID: 9973112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
    Kobayashi K; Noguchi M; Itoh K; Harada M
    Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
    Lu J; Celis E
    Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
    Tjoa B; Boynton A; Kenny G; Ragde H; Misrock SL; Murphy G
    Prostate; 1996 Jan; 28(1):65-9. PubMed ID: 8545283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
    Tjoa BA; Simmons SJ; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL; Murphy GP
    Prostate; 1998 Jun; 36(1):39-44. PubMed ID: 9650914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
    Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up evaluation of a phase II prostate cancer vaccine trial.
    Tjoa BA; Simmons SJ; Elgamal A; Rogers M; Ragde H; Kenny GM; Troychak MJ; Boynton AL; Murphy GP
    Prostate; 1999 Jul; 40(2):125-9. PubMed ID: 10386473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Active specific immune therapy of prostate gland cancer].
    Chakŭrov S; Minchev M
    Khirurgiia (Sofiia); 2002; 58(1):32-8. PubMed ID: 12515033
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
    Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
    Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
    Knight D; Peterson AC; Rini BI; Harlin H; Gajewski TF; Stadler WM
    Prostate; 2009 Feb; 69(2):142-8. PubMed ID: 18942640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.
    Fishman M
    Expert Opin Biol Ther; 2009 Dec; 9(12):1565-75. PubMed ID: 19916735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-based immunotherapy of prostate cancer.
    Salgaller ML; Tjoa BA; Lodge PA; Ragde H; Kenny G; Boynton A; Murphy GP
    Crit Rev Immunol; 1998; 18(1-2):109-19. PubMed ID: 9419453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.